Wall Street Zen Upgrades Merck & Co., Inc. (NYSE:MRK) to “Buy”

Merck & Co., Inc. (NYSE:MRK) was upgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a report released on Sunday, Wall Street Zen reports.

A number of other brokerages have also commented on MRK. UBS Group upped their price target on Merck & Co., Inc. from $145.00 to $175.00 and gave the stock a “buy” rating in a report on Thursday, August 20th. Guggenheim raised their price objective on shares of Merck & Co., Inc. from $146.00 to $170.00 and gave the stock a “buy” rating in a research note on Tuesday, September 8th. Wells Fargo & Company boosted their target price on shares of Merck & Co., Inc. from $150.00 to $170.00 and gave the stock an “overweight” rating in a research report on Friday, September 4th. CICC Research assumed coverage on shares of Merck & Co., Inc. in a research note on Wednesday, June 24th. They set an “outperform” rating and a $138.00 target price for the company. Finally, Barclays increased their price target on shares of Merck & Co., Inc. from $140.00 to $150.00 and gave the company an “overweight” rating in a report on Wednesday, July 29th. Seventeen equities research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $154.24.

Merck & Co., Inc. Trading Up 2.1%

Shares of NYSE MRK opened at $150.00 on Friday. The stock has a market cap of $370.08 billion, a price-to-earnings ratio of 120.00, a PEG ratio of 6.39 and a beta of 0.21. The business has a 50 day simple moving average of $138.97 and a 200 day simple moving average of $125.44. Merck & Co., Inc. has a 52 week low of $77.58 and a 52 week high of $156.92. The company has a debt-to-equity ratio of 1.22, a quick ratio of 1.10 and a current ratio of 1.32.

Merck & Co., Inc. (NYSE:MRK) last posted its earnings results on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.13. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The firm had revenue of $16.61 billion for the quarter, compared to the consensus estimate of $16.37 billion. During the same period in the prior year, the business posted $2.13 earnings per share. The business’s quarterly revenue was up 5.1% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. On average, research analysts predict that Merck & Co., Inc. will post 2.76 earnings per share for the current fiscal year.

Insider Buying and Selling at Merck & Co., Inc.

In other Merck & Co., Inc. news, EVP David Maraldo sold 18,706 shares of the business’s stock in a transaction dated Wednesday, August 5th. The stock was sold at an average price of $128.72, for a total transaction of $2,407,836.32. Following the completion of the sale, the executive vice president directly owned 18,212 shares of the company’s stock, valued at approximately $2,344,248.64. The trade was a 50.67% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Chirfi Guindo sold 10,000 shares of Merck & Co., Inc. stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $135.00, for a total transaction of $1,350,000.00. Following the sale, the executive vice president directly owned 36,613 shares of the company’s stock, valued at $4,942,755. This represents a 21.45% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 228,238 shares of company stock valued at $29,977,783 over the last three months. Insiders own 0.17% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Bullseye Investment Management LLC bought a new position in shares of Merck & Co., Inc. during the second quarter worth $27,000. Kingdom Financial Group LLC. acquired a new stake in Merck & Co., Inc. during the 4th quarter worth $25,000. Abound Financial LLC bought a new position in Merck & Co., Inc. during the fourth quarter worth about $26,000. Graney & King LLC lifted its holdings in Merck & Co., Inc. by 400.0% during the second quarter. Graney & King LLC now owns 250 shares of the company’s stock worth $32,000 after acquiring an additional 200 shares in the last quarter. Finally, Montgomery Financial Services LLC acquired a new position in Merck & Co., Inc. in the second quarter valued at about $41,000. Institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. News Roundup

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: European support for Keytruda-Padcev: The European Medicines Agency’s CHMP recommended approval of the Keytruda-Padcev combination as a perioperative treatment for eligible patients with resectable muscle-invasive bladder cancer. The recommendation expands the potential use of Merck’s flagship immunotherapy, although final European Commission approval is still required. Merck Gets CHMP Backing for Keytruda-Padcev Combo in Bladder Cancer
• Positive Sentiment: Japan approves subcutaneous Keytruda: Japan’s health ministry approved KEYTRUDA QLEX, also planned to be marketed as KEYJECT, for subcutaneous administration across all approved Japanese Keytruda indications. The easier-to-administer formulation could improve patient convenience and support the product’s lifecycle and commercial durability. Merck’s KEYTRUDA QLEX Approved in Japan
• Positive Sentiment: Positive read-through from Moderna’s melanoma program: Moderna’s Phase 3 melanoma data received a prominent oncology-congress presentation slot, lifting Moderna and providing a favorable read-through for Merck because the program involves a cancer vaccine developed with Keytruda. The actual data have not yet been disclosed, limiting the certainty of this catalyst. Moderna Melanoma Data Wins Presidential Symposium Slot
• Neutral Sentiment: Merck is among companies facing important regulatory decisions this week, keeping attention on possible near-term catalysts, but the reports do not identify a new decision or outcome for MRK. A comparison of Merck and AstraZeneca highlights Keytruda growth, pipeline potential and patent risks without introducing new company-specific information. FDA Decision Watch
• Neutral Sentiment: Merck Canada’s sponsorship of a Montreal Museum of Fine Arts exhibition is a corporate-branding initiative with little expected effect on earnings or the stock. Merck Canada Partners with Montreal Museum of Fine Arts
• Negative Sentiment: A bearish analyst view argues that MRK has become overvalued and overbought after its recent rally, raising the risk of consolidation or profit-taking despite the favorable product news. Merck: Time To Trim, Overvalued, And Overbought

About Merck & Co., Inc.

Merck & Co, Inc is a global healthcare company that develops, manufactures, and markets prescription medicines, vaccines, and animal-health products. The company serves patients, healthcare providers, and customers in markets worldwide through its Human Health and Animal Health businesses.

Merck’s pharmaceutical portfolio includes oncology, infectious disease, cardiology, immunology, and other therapeutic areas. Its products include Keytruda, an immunotherapy used to treat various cancers; Gardasil, a vaccine that helps protect against human papillomavirus (HPV); and Januvia, a treatment for type 2 diabetes.